4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Head-up Position and High Quality Cardiopulmonary Resuscitation in OHCA (GRAVITY)

Head-up Position and High Quality Cardiopulmonary Resuscitation in OHCA (GRAVITY)

Study Description
Brief Summary:

Elevation of the head and thorax, also known as Head-up cardiopulmonary resuscitation (HUP CPR), has been studied extensively in pigs in ventricular fibrillation (VF). HUP combined with active compression decompression and impedance threshold device (ACD+ITD) CPR improves vital organ perfusion and results in a doubling of cerebral perfusion when compared with the same method of CPR in the flat or horizontal plane. HUP CPR enhances the drainage of venous blood from the brain, lowers central venous pressures, reduces intracranial pressures during the decompression phase of CPR, redistributes blood flow through the lungs during CPR, and may reduce brain edema. These mechanisms collectively contribute to improved blood flow and less injury to the brain during CPR. These benefits are due in large part to the effects of gravity on the physiology of HUP CPR. Importantly, HUP CPR is dependent upon a means of generating enough forward flow to adequately pump blood "uphill" to the brain.

In this proposed pilot study, CPR will be performed manually before the patient is placed on a controlled mechanical elevation device (Elegard, Minnesota Resuscitation Solutions LLC, USA). An ITD-16 (ResQPOD-16, Zoll, USA) will be placed on the patient's airway before the head is elevated. Automated CPR will be initiated as soon as feasible using a new automated CPR mechanical compression device that provides full active compression-decompression CPR (LUCAS-AD, Stryker, USA).

The proposed feasibility clinical study will be the first ever to test the fully integrated system of ACD+ITD HUP CPR.


Condition or disease Intervention/treatment Phase
Cardiac Arrest Device: Head UP Position Device: Impedance Threshold Device Device: New Automated CPR Not Applicable

Detailed Description:

Elevation of the head and thorax, also known as Head-up cardiopulmonary resuscitation (HUP CPR), has been studied extensively in pigs in ventricular fibrillation (VF). HUP combined with active compression decompression and impedance threshold device (ACD+ITD) CPR improves vital organ perfusion and results in a doubling of cerebral perfusion when compared with the same method of CPR in the flat or horizontal plane. HUP CPR enhances the drainage of venous blood from the brain, lowers central venous pressures, reduces intracranial pressures during the decompression phase of CPR, redistributes blood flow through the lungs during CPR, and may reduce brain edema. These mechanisms collectively contribute to improved blood flow and less injury to the brain during CPR. These benefits are due in large part to the effects of gravity on the physiology of HUP CPR. Importantly, HUP CPR is dependent upon a means of generating enough forward flow to adequately pump blood "uphill" to the brain.

Animal studies have shown that HUP CPR must be performed in a specific manner to be effective. For example, conventional standard CPR is insufficient, by itself, for effective HUP CPR. Additional means to enhance circulation are needed, such as concurrent use of the ITD and ACD CPR devices. ACD+ITD CPR alone has been shown to improve hemodynamics and survival with favorable neurologic outcome in several human randomized control trials. Animal studies have shown that HUP CPR is best with the combination of ACD+ITD CPR. Studies have shown that CPR must be initiated before elevating the head. Studies have also shown that HUP CPR is dependent upon the time it takes to elevate the head to the HUP. Elevation of the head and thorax should optimally take place over a 2-minute period of time from a flat position to the maximum head up elevation level in order to optimize cerebral perfusion pressures. Too rapid an elevation of the head and thorax can result in a reduction in cerebral arterial pressure when compared with flat CPR.

In this proposed pilot study, CPR will be performed manually before the patient is placed on a controlled mechanical elevation device (Elegard, Minnesota Resuscitation Solutions LLC, USA). An ITD-16 (ResQPOD-16, Zoll, USA) will be placed on the patient's airway before the head is elevated. Automated CPR will be initiated as soon as feasible using a new automated CPR mechanical compression device that provides full active compression-decompression CPR (LUCAS-AD, Stryker, USA).

The proposed feasibility clinical study will be the first ever to test the fully integrated system of ACD+ITD HUP CPR.

Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 194 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Prospective, quasi-experimental, controlled, pre- and post-intervention trial, using a difference-in-differences design and involving two study sites
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Head-up Position, Active Compression-decompression Mechanical Cardiopulmonary Resuscitation and Impedance Threshold Device to Improve Outcomes in Out-of-hospital Cardiac Arrest. A Multicenter Prospective Controlled Quasi-experimental Trial
Actual Study Start Date : October 9, 2019
Estimated Primary Completion Date : October 9, 2021
Estimated Study Completion Date : January 2022
Arms and Interventions
Arm Intervention/treatment
No Intervention: Control Group

During the pre-intervention period, patients will receive standard CPR in the two study groups. Standard CPR will be performed according to the current guidelines.

The only changes in current practice for the control will be the monitoring of EtCO2 and cerebral oxymetry as early as possible for the firefighter. ETCO2 will be recorded using a small portable ETCO2 monitor (EMMA, Masimo, USA). EMS first responders will receive a specific training in both group to use, recording, and reporting of ETCO2 value during CPR. This device has CE mark (see related CE mark and user manual). Cerebral oximetry will be recorded using a new small portable device (HR500, Nonin, USA). This device allows using an easy to use adhesive sensor with remote Bluetooth connection to a smartphone sized monitor.

Active Comparator: Assigned Intervention
During the post-intervention period, patients assigned in the intervention group will receive the evaluated intervention (i.e., HUP and ACD-ITD CPR HUP using the 3 devices in combinations, Elegard, Lucas AD and ITD-16)
Device: Head UP Position

CPR will be performed manually before the patient is placed on a controlled mechanical elevation device who raises the head and thorax, also known as the head-up position (HUP-Elegard, Minnesota Resuscitation Solutions LLC, USA).

Rescuers will perform CPR as continuously as possible during the placement of the Elegard, with a <10 second pause in chest compressions during the placement of this device. After performing (LUCAS AD + ITD CPR, see other interventions below) for 2 minutes with the head in the 'flat' position, the Elegard device will be turned on and the head will begin to rise as long as the patient is being treated with the ResQPOD-16 and the LUCAS AD. The head will be elevated to approximately 22 cm from the ground to the back of the occiput.


Device: Impedance Threshold Device
An an impedance threshold device ITD-16 (ResQPOD-16, Zoll, USA) will be placed on the patient's airway before the head is elevated.

Device: New Automated CPR
Automated CPR will be initiated as soon as feasible using a new automated CPR mechanical compression device that provides full active compression-decompression CPR (LUCAS-AD, Stryker, USA).

Outcome Measures
Primary Outcome Measures :
  1. Maximum End-tidal carbon dioxide (ETCO2) [ Time Frame: Day 0 ]
    The maximum value of ETCO2 during CPR before ROSC measured after a washout period of 4 positive pressure ventilations (~30 seconds with 30:2 compression: ventilation ratio) will be recorded. ETCO2 value reflects both cardiac output (CO) and pulmonary blood flow, and is an indirect indicator of coronary perfusion pressure during CPR. Levels of ETCO2 > 10-15 mmHg have been correlated with return of spontaneous circulation (ROSC) and survival in both animal and human models of cardiac arrest.


Secondary Outcome Measures :
  1. Return of spontaneous circulation (ROSC) [ Time Frame: Day 0 ]
    Proportion of patients who's recovered a spontaneous circulation after CPR

  2. Alive at hospital admission [ Time Frame: Day 0 ]
    Vital status at hospital admission

  3. Survival to hospital discharge [ Time Frame: up to 30 days ]
    Vital status at hospital discharge

  4. Survival at 30 days [ Time Frame: 30 days ]
    Vital status at 30 days

  5. Neurological functional status [ Time Frame: Day 30 ]
    As measured by using the modified Rankin Scale (mRS). A score equal to 0 = no symptoms at all, A score equal to 1 = no significant disability, despite symptoms ; able to carry out all usual duties and activities A score equal to 2 = slight disability ; unable to carry out all previous activities but able to look after own affairs A score equal to 3 = moderate disability ; requiring some help, but able to walk without assistance A score equal to 4 = moderately severe disbility ; unable to walk without assistance and unable to attend to own bodily needs without assistance A score equal to 5 = severe disability ; bedridden, incontinent and requiring constant nursing care and attention We consired to a score less or equal to 3 will be considered as favourable neurologic outcome

  6. First recorded rhythm [ Time Frame: Day 0 ]
    First recorded rhythm and rhythm recorded by EMS (asystole, ryhtme without pulse, ventricular fibrillation or ventricular tacycardia and spontaneous circulation)

  7. Changes in heart rhythm from ventricular fibrillation (VF) [ Time Frame: Day 0 ]
    Proportion of patients who's with changes in heart rhythm from VF to non-VF rhythm and vice versa during the EMS intervention

  8. Signs of life [ Time Frame: Day 0 ]
    Presence of agonal respirations and other signs of life (pupillary response, movement during CPR) recorded by ALS

  9. Re-arrest rates [ Time Frame: Day 0 ]
    We calculated the proportion of patients who's recovered another cardiac arrest during CPR (supported by ALS and EMS)

  10. Non-invasive arterial O2 [ Time Frame: Day 0 ]
    Non-invasive arterial O2 saturation values during CPR recorded by EMS

  11. End-tidal carbon dioxide (ETCO2) after CPR initiation [ Time Frame: Day 0 ]
    We compared the difference in ETCO2 values between baseline (i.e., within 2 minutes of CPR initiation) and repeated (i.e., within 4 minutes of CPR initiation) measures during the CPR (recorded by ALS and EMS intervention)

  12. Non-invasive cerebral oximetry (rsO2) [ Time Frame: Day 0 ]
    Non-invasive cerebral oximetry (rsO2) values during CPR repeated (i.e., within 4 minutes of CPR initiation) measures recorded by ALS and EMS intervention

  13. Left Ventricular (LV) function [ Time Frame: Day 0 ]
    LV function will be measured by echocardiography within 12 hours of ROSC at hospital

  14. Non-invasive measurement of blood pressure [ Time Frame: Day 0 ]
    Non-invasive measurement of blood (systolic, diastolic and mean blood pressure) pressure during CPR

  15. Intubation difficulty [ Time Frame: Day 0 ]
    Intubation difficulty assessed by the Intubation Difficulty Scale score. Score equal at 0 will be considered to easy intubation, score between 0 and 5 will be considered to slight difficulty, score more than 5 will be considered to moderate to major difficulty and score equal to infinite will be considered to impossible intubation

  16. Neuron specific enolase [ Time Frame: Day 0 and 24hours ]
    Serum Neuron specific enolase was measured at admission and 24h after hospital admission

  17. S100 protein [ Time Frame: Day 0 and 24hours ]
    Serum S100 protein was measured- at admission and 24h after hospital admission

  18. Arterial Blood gases [ Time Frame: Day 0 ]
    Arterial blood gases (PaO2 partial pressure of oxygen, PCO2 partial pressure of cardon dioxide, pH, HCO3- bicarbonates and SaO2 oxygen saturation) were measured at hospital admission

  19. Serum lactate concentration [ Time Frame: Day 0 ]
    The serum lactate concentration was measured at hospital admission

  20. Serum d-dimer concentration [ Time Frame: Day 0 and 24hours ]
    Serum d-dimer concentration was measured at 4hour and 24 hour after admission

  21. Troponin C serum concentration [ Time Frame: Day 0 and 24hours ]
    Troponin C serum concentration was measured at 4hour and 24 hour after admission

  22. Creatinine concentration [ Time Frame: Day 0 and 24hours ]
    Serum creatinine concentration was measured at 4hour and 24 hour after admission

  23. Transaminases concentration [ Time Frame: Day 0 and 24hours ]
    Serum transaminases concentration (ASAT: aspartate aminotransferases and ALAT: alanine aminotransferases) were measured at 4hour and 24 hour after admission

  24. Imaging [ Time Frame: 12 hours ]
    Head CT will be performed within 12 hours of ROSC. Analysis will include the white to gray matter ratio

  25. End-tidal carbon dioxide between witnessed and unwitnessed cardiac arrest out-of-hospital cardiac arrest [ Time Frame: Day 0 ]
    We compared the difference in maximum ETCO2 during CPR between values recorded for witnessed and unwitnessed cardiac arrest

  26. ROSC for witnessed and unwitnessed cardiac arrest [ Time Frame: Day 0 ]
    Proportion of patients who's recovered a spontaneous circulation after CPR between witnessed and unwitnessed cardiac arrest

  27. Survival to hospital admission for witnessed and unwitnessed cardiac arrest [ Time Frame: Day 0 ]
    Vital status at hospital admission between witnessed and unwitnessed cardiac arrest

  28. Survival to hospital discharge for witnessed and unwitnessed cardiac arrest [ Time Frame: Up to 30 days ]
    Vital status at hospital discharge between witnessed and unwitnessed cardiac arrest

  29. Neurological functional status between witnessed and unwitnessed cardiac arrest [ Time Frame: Up to 30 days ]
    As measured by using the modified Rankin Scale (mRS). A score equal to 0 = no symptoms at all, A score equal to 1 = no significant disability, despite symptoms ; able to carry out all usual duties and activities A score equal to 2 = slight disability ; unable to carry out all previous activities but able to look after own affairs A score equal to 3 = moderate disability ; requiring some help, but able to walk without assistance A score equal to 4 = moderately severe disbility ; unable to walk without assistance and unable to attend to own bodily needs without assistance A score equal to 5 = severe disability ; bedridden, incontinent and requiring constant nursing care and attention We consired to a score less or equal to 3 will be considered as favourable neurologic outcome


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age > 18 years old on enrollment
  • Witnessed out-of-hospital cardiac arrest

Exclusion Criteria:

  • Obvious pregnancy at inclusion
  • Cardiac arrest of traumatic origin (including drowning or hanging)
  • Cardiac arrest for which resuscitation seems unjustified (inevitable death, terminally ill irreversible condition, too long duration of cardiac arrest, advance personal directives of no-resuscitation)
Contacts and Locations

Contacts
Layout table for location contacts
Contact: Guillaume DEBATY, MD 0033476634202 gdebaty@chu-grenoble.fr
Contact: Caroline Sanchez, PhD 0033476634256 csanchez5@chu-grenoble.fr

Locations
Layout table for location information
France
SAMU 38 Recruiting
Grenoble, Isère, France, 38000
Contact: Guillaume Debaty, Md, PhD       gdebaty@chu-grenoble.fr   
SAMU 54 - CHU Nancy Not yet recruiting
Nancy, Meurthe-et-Moselle, France, 54000
Contact: Chouihed Tahar, MD, PhD       t.chouihed@gmail.com   
Sponsors and Collaborators
University Hospital, Grenoble
Investigators
Layout table for investigator information
Study Director: Monique Sorentino CHU Grenoble Alpes
Tracking Information
First Submitted Date  ICMJE June 17, 2019
First Posted Date  ICMJE June 25, 2019
Last Update Posted Date December 17, 2020
Actual Study Start Date  ICMJE October 9, 2019
Estimated Primary Completion Date October 9, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 15, 2020)
Maximum End-tidal carbon dioxide (ETCO2) [ Time Frame: Day 0 ]
The maximum value of ETCO2 during CPR before ROSC measured after a washout period of 4 positive pressure ventilations (~30 seconds with 30:2 compression: ventilation ratio) will be recorded. ETCO2 value reflects both cardiac output (CO) and pulmonary blood flow, and is an indirect indicator of coronary perfusion pressure during CPR. Levels of ETCO2 > 10-15 mmHg have been correlated with return of spontaneous circulation (ROSC) and survival in both animal and human models of cardiac arrest.
Original Primary Outcome Measures  ICMJE
 (submitted: June 20, 2019)
End-tidal carbon dioxide (ETCO2) [ Time Frame: Day 0 ]
The maximum value of ETCO2 during CPR before ROSC measured after a washout period of 4 positive pressure ventilations (~30 seconds with 30:2 compression: ventilation ratio) will be recorded. ETCO2 value reflects both cardiac output (CO) and pulmonary blood flow, and is an indirect indicator of coronary perfusion pressure during CPR. Levels of ETCO2 > 10-15 mmHg have been correlated with return of spontaneous circulation (ROSC) and survival in both animal and human models of cardiac arrest.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 15, 2020)
  • Return of spontaneous circulation (ROSC) [ Time Frame: Day 0 ]
    Proportion of patients who's recovered a spontaneous circulation after CPR
  • Alive at hospital admission [ Time Frame: Day 0 ]
    Vital status at hospital admission
  • Survival to hospital discharge [ Time Frame: up to 30 days ]
    Vital status at hospital discharge
  • Survival at 30 days [ Time Frame: 30 days ]
    Vital status at 30 days
  • Neurological functional status [ Time Frame: Day 30 ]
    As measured by using the modified Rankin Scale (mRS). A score equal to 0 = no symptoms at all, A score equal to 1 = no significant disability, despite symptoms ; able to carry out all usual duties and activities A score equal to 2 = slight disability ; unable to carry out all previous activities but able to look after own affairs A score equal to 3 = moderate disability ; requiring some help, but able to walk without assistance A score equal to 4 = moderately severe disbility ; unable to walk without assistance and unable to attend to own bodily needs without assistance A score equal to 5 = severe disability ; bedridden, incontinent and requiring constant nursing care and attention We consired to a score less or equal to 3 will be considered as favourable neurologic outcome
  • First recorded rhythm [ Time Frame: Day 0 ]
    First recorded rhythm and rhythm recorded by EMS (asystole, ryhtme without pulse, ventricular fibrillation or ventricular tacycardia and spontaneous circulation)
  • Changes in heart rhythm from ventricular fibrillation (VF) [ Time Frame: Day 0 ]
    Proportion of patients who's with changes in heart rhythm from VF to non-VF rhythm and vice versa during the EMS intervention
  • Signs of life [ Time Frame: Day 0 ]
    Presence of agonal respirations and other signs of life (pupillary response, movement during CPR) recorded by ALS
  • Re-arrest rates [ Time Frame: Day 0 ]
    We calculated the proportion of patients who's recovered another cardiac arrest during CPR (supported by ALS and EMS)
  • Non-invasive arterial O2 [ Time Frame: Day 0 ]
    Non-invasive arterial O2 saturation values during CPR recorded by EMS
  • End-tidal carbon dioxide (ETCO2) after CPR initiation [ Time Frame: Day 0 ]
    We compared the difference in ETCO2 values between baseline (i.e., within 2 minutes of CPR initiation) and repeated (i.e., within 4 minutes of CPR initiation) measures during the CPR (recorded by ALS and EMS intervention)
  • Non-invasive cerebral oximetry (rsO2) [ Time Frame: Day 0 ]
    Non-invasive cerebral oximetry (rsO2) values during CPR repeated (i.e., within 4 minutes of CPR initiation) measures recorded by ALS and EMS intervention
  • Left Ventricular (LV) function [ Time Frame: Day 0 ]
    LV function will be measured by echocardiography within 12 hours of ROSC at hospital
  • Non-invasive measurement of blood pressure [ Time Frame: Day 0 ]
    Non-invasive measurement of blood (systolic, diastolic and mean blood pressure) pressure during CPR
  • Intubation difficulty [ Time Frame: Day 0 ]
    Intubation difficulty assessed by the Intubation Difficulty Scale score. Score equal at 0 will be considered to easy intubation, score between 0 and 5 will be considered to slight difficulty, score more than 5 will be considered to moderate to major difficulty and score equal to infinite will be considered to impossible intubation
  • Neuron specific enolase [ Time Frame: Day 0 and 24hours ]
    Serum Neuron specific enolase was measured at admission and 24h after hospital admission
  • S100 protein [ Time Frame: Day 0 and 24hours ]
    Serum S100 protein was measured- at admission and 24h after hospital admission
  • Arterial Blood gases [ Time Frame: Day 0 ]
    Arterial blood gases (PaO2 partial pressure of oxygen, PCO2 partial pressure of cardon dioxide, pH, HCO3- bicarbonates and SaO2 oxygen saturation) were measured at hospital admission
  • Serum lactate concentration [ Time Frame: Day 0 ]
    The serum lactate concentration was measured at hospital admission
  • Serum d-dimer concentration [ Time Frame: Day 0 and 24hours ]
    Serum d-dimer concentration was measured at 4hour and 24 hour after admission
  • Troponin C serum concentration [ Time Frame: Day 0 and 24hours ]
    Troponin C serum concentration was measured at 4hour and 24 hour after admission
  • Creatinine concentration [ Time Frame: Day 0 and 24hours ]
    Serum creatinine concentration was measured at 4hour and 24 hour after admission
  • Transaminases concentration [ Time Frame: Day 0 and 24hours ]
    Serum transaminases concentration (ASAT: aspartate aminotransferases and ALAT: alanine aminotransferases) were measured at 4hour and 24 hour after admission
  • Imaging [ Time Frame: 12 hours ]
    Head CT will be performed within 12 hours of ROSC. Analysis will include the white to gray matter ratio
  • End-tidal carbon dioxide between witnessed and unwitnessed cardiac arrest out-of-hospital cardiac arrest [ Time Frame: Day 0 ]
    We compared the difference in maximum ETCO2 during CPR between values recorded for witnessed and unwitnessed cardiac arrest
  • ROSC for witnessed and unwitnessed cardiac arrest [ Time Frame: Day 0 ]
    Proportion of patients who's recovered a spontaneous circulation after CPR between witnessed and unwitnessed cardiac arrest
  • Survival to hospital admission for witnessed and unwitnessed cardiac arrest [ Time Frame: Day 0 ]
    Vital status at hospital admission between witnessed and unwitnessed cardiac arrest
  • Survival to hospital discharge for witnessed and unwitnessed cardiac arrest [ Time Frame: Up to 30 days ]
    Vital status at hospital discharge between witnessed and unwitnessed cardiac arrest
  • Neurological functional status between witnessed and unwitnessed cardiac arrest [ Time Frame: Up to 30 days ]
    As measured by using the modified Rankin Scale (mRS). A score equal to 0 = no symptoms at all, A score equal to 1 = no significant disability, despite symptoms ; able to carry out all usual duties and activities A score equal to 2 = slight disability ; unable to carry out all previous activities but able to look after own affairs A score equal to 3 = moderate disability ; requiring some help, but able to walk without assistance A score equal to 4 = moderately severe disbility ; unable to walk without assistance and unable to attend to own bodily needs without assistance A score equal to 5 = severe disability ; bedridden, incontinent and requiring constant nursing care and attention We consired to a score less or equal to 3 will be considered as favourable neurologic outcome
Original Secondary Outcome Measures  ICMJE
 (submitted: June 20, 2019)
  • Return of spontaneous circulation (ROSC) [ Time Frame: Day 0 ]
    Proportion of patients who's recovered a spontaneous circulation after CPR
  • Alive at hospital admission [ Time Frame: Day 0 ]
    Vital status at hospital admission
  • Survival to hospital discharge [ Time Frame: up to 30 days ]
    Vital status at hospital discharge
  • Survival at 30 days [ Time Frame: 30 days ]
    Vital status at 30 days
  • Neurological functional status [ Time Frame: Day 30 ]
    As measured by using the modified Rankin Scale (a mRS score less or equal to 3 will be considered as favourable neurologic outcome)
  • First recorded rhythm [ Time Frame: Day 0 ]
    First recorded rhythm and rhythm recorded by EMS (asystole, ryhtme without pulse, ventricular fibrillation or ventricular tacycardia and spontaneous circulation)
  • Changes in heart rhythm from ventricular fibrillation (VF) [ Time Frame: Day 0 ]
    Proportion of patients who's with changes in heart rhythm from VF to non-VF rhythm and vice versa during the EMS intervention
  • Signs of life [ Time Frame: Day 0 ]
    Presence of agonal respirations and other signs of life (pupillary response, movement during CPR) recorded by ALS
  • Re-arrest rates [ Time Frame: Day 0 ]
    We calculated the proportion of patients who's recovered another cardiac arrest during CPR (supported by ALS and EMS)
  • Non-invasive arterial O2 [ Time Frame: Day 0 ]
    Non-invasive arterial O2 saturation values during CPR recorded by EMS
  • End-tidal carbon dioxide (ETCO2) [ Time Frame: Day 0 ]
    We compared the difference in ETCO2 values between baseline (i.e., within 2 minutes of CPR initiation) and repeated (i.e., within 4 minutes of CPR initiation) measures during the CPR (recorded by ALS and EMS intervention)
  • Non-invasive cerebral oximetry (rsO2) [ Time Frame: Day 0 ]
    Non-invasive cerebral oximetry (rsO2) values during CPR repeated (i.e., within 4 minutes of CPR initiation) measures recorded by ALS and EMS intervention
  • Left Ventricular (LV) function [ Time Frame: Day 0 ]
    LV function will be measured by echocardiography within 12 hours of ROSC at hospital
  • Non-invasive measurement of blood pressure [ Time Frame: Day 0 ]
    Non-invasive measurement of blood (systolic, diastolic and mean blood pressure) pressure during CPR
  • Intubation difficulty [ Time Frame: Day 0 ]
    Intubation difficulty assessed by the Intubation Difficulty Scale score. Score equal at 0 will be considered to easy intubation, score between 0 and 5 will be considered to slight difficulty, score more than 5 will be considered to moderate to major difficulty and score equal to infinite will be considered to impossible intubation
  • Neuron specific enolase [ Time Frame: Day 0 and 24hours ]
    Serum Neuron specific enolase was measured at admission and 24h after hospital admission
  • S100 protein [ Time Frame: Day 0 and 24hours ]
    Serum S100 protein was measured- at admission and 24h after hospital admission
  • Arterial Blood gases [ Time Frame: Day 0 ]
    Arterial blood gases (PaO2 partial pressure of oxygen, PCO2 partial pressure of cardon dioxide, pH, HCO3- bicarbonates and SaO2 oxygen saturation) were measured at hospital admission
  • Serum lactate [ Time Frame: Day 0 ]
    Serum lactate was measured at hospital admission
  • Serum d-dimer [ Time Frame: Day 0 and 24hours ]
    Serum d-dimer was measured at 4hour and 24 hour after admission
  • Troponin C [ Time Frame: Day 0 and 24hours ]
    Troponin C was measured at 4hour and 24 hour after admission
  • Creatinine [ Time Frame: Day 0 and 24hours ]
    creatinine, ASAT and ALAT were measured at 4hour and 24 hour after admission
  • Transaminases [ Time Frame: Day 0 and 24hours ]
    The transaminases (ASAT: aspartate aminotransferases and ALAT: alanine aminotransferases) were measured at 4hour and 24 hour after admission
  • Imaging [ Time Frame: 12 hours ]
    Head CT will be performed within 12 hours of ROSC. Analysis will include the white to gray matter ratio
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Head-up Position and High Quality Cardiopulmonary Resuscitation in OHCA
Official Title  ICMJE Head-up Position, Active Compression-decompression Mechanical Cardiopulmonary Resuscitation and Impedance Threshold Device to Improve Outcomes in Out-of-hospital Cardiac Arrest. A Multicenter Prospective Controlled Quasi-experimental Trial
Brief Summary

Elevation of the head and thorax, also known as Head-up cardiopulmonary resuscitation (HUP CPR), has been studied extensively in pigs in ventricular fibrillation (VF). HUP combined with active compression decompression and impedance threshold device (ACD+ITD) CPR improves vital organ perfusion and results in a doubling of cerebral perfusion when compared with the same method of CPR in the flat or horizontal plane. HUP CPR enhances the drainage of venous blood from the brain, lowers central venous pressures, reduces intracranial pressures during the decompression phase of CPR, redistributes blood flow through the lungs during CPR, and may reduce brain edema. These mechanisms collectively contribute to improved blood flow and less injury to the brain during CPR. These benefits are due in large part to the effects of gravity on the physiology of HUP CPR. Importantly, HUP CPR is dependent upon a means of generating enough forward flow to adequately pump blood "uphill" to the brain.

In this proposed pilot study, CPR will be performed manually before the patient is placed on a controlled mechanical elevation device (Elegard, Minnesota Resuscitation Solutions LLC, USA). An ITD-16 (ResQPOD-16, Zoll, USA) will be placed on the patient's airway before the head is elevated. Automated CPR will be initiated as soon as feasible using a new automated CPR mechanical compression device that provides full active compression-decompression CPR (LUCAS-AD, Stryker, USA).

The proposed feasibility clinical study will be the first ever to test the fully integrated system of ACD+ITD HUP CPR.

Detailed Description

Elevation of the head and thorax, also known as Head-up cardiopulmonary resuscitation (HUP CPR), has been studied extensively in pigs in ventricular fibrillation (VF). HUP combined with active compression decompression and impedance threshold device (ACD+ITD) CPR improves vital organ perfusion and results in a doubling of cerebral perfusion when compared with the same method of CPR in the flat or horizontal plane. HUP CPR enhances the drainage of venous blood from the brain, lowers central venous pressures, reduces intracranial pressures during the decompression phase of CPR, redistributes blood flow through the lungs during CPR, and may reduce brain edema. These mechanisms collectively contribute to improved blood flow and less injury to the brain during CPR. These benefits are due in large part to the effects of gravity on the physiology of HUP CPR. Importantly, HUP CPR is dependent upon a means of generating enough forward flow to adequately pump blood "uphill" to the brain.

Animal studies have shown that HUP CPR must be performed in a specific manner to be effective. For example, conventional standard CPR is insufficient, by itself, for effective HUP CPR. Additional means to enhance circulation are needed, such as concurrent use of the ITD and ACD CPR devices. ACD+ITD CPR alone has been shown to improve hemodynamics and survival with favorable neurologic outcome in several human randomized control trials. Animal studies have shown that HUP CPR is best with the combination of ACD+ITD CPR. Studies have shown that CPR must be initiated before elevating the head. Studies have also shown that HUP CPR is dependent upon the time it takes to elevate the head to the HUP. Elevation of the head and thorax should optimally take place over a 2-minute period of time from a flat position to the maximum head up elevation level in order to optimize cerebral perfusion pressures. Too rapid an elevation of the head and thorax can result in a reduction in cerebral arterial pressure when compared with flat CPR.

In this proposed pilot study, CPR will be performed manually before the patient is placed on a controlled mechanical elevation device (Elegard, Minnesota Resuscitation Solutions LLC, USA). An ITD-16 (ResQPOD-16, Zoll, USA) will be placed on the patient's airway before the head is elevated. Automated CPR will be initiated as soon as feasible using a new automated CPR mechanical compression device that provides full active compression-decompression CPR (LUCAS-AD, Stryker, USA).

The proposed feasibility clinical study will be the first ever to test the fully integrated system of ACD+ITD HUP CPR.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Prospective, quasi-experimental, controlled, pre- and post-intervention trial, using a difference-in-differences design and involving two study sites
Masking: None (Open Label)
Primary Purpose: Other
Condition  ICMJE Cardiac Arrest
Intervention  ICMJE
  • Device: Head UP Position

    CPR will be performed manually before the patient is placed on a controlled mechanical elevation device who raises the head and thorax, also known as the head-up position (HUP-Elegard, Minnesota Resuscitation Solutions LLC, USA).

    Rescuers will perform CPR as continuously as possible during the placement of the Elegard, with a <10 second pause in chest compressions during the placement of this device. After performing (LUCAS AD + ITD CPR, see other interventions below) for 2 minutes with the head in the 'flat' position, the Elegard device will be turned on and the head will begin to rise as long as the patient is being treated with the ResQPOD-16 and the LUCAS AD. The head will be elevated to approximately 22 cm from the ground to the back of the occiput.

  • Device: Impedance Threshold Device
    An an impedance threshold device ITD-16 (ResQPOD-16, Zoll, USA) will be placed on the patient's airway before the head is elevated.
  • Device: New Automated CPR
    Automated CPR will be initiated as soon as feasible using a new automated CPR mechanical compression device that provides full active compression-decompression CPR (LUCAS-AD, Stryker, USA).
Study Arms  ICMJE
  • No Intervention: Control Group

    During the pre-intervention period, patients will receive standard CPR in the two study groups. Standard CPR will be performed according to the current guidelines.

    The only changes in current practice for the control will be the monitoring of EtCO2 and cerebral oxymetry as early as possible for the firefighter. ETCO2 will be recorded using a small portable ETCO2 monitor (EMMA, Masimo, USA). EMS first responders will receive a specific training in both group to use, recording, and reporting of ETCO2 value during CPR. This device has CE mark (see related CE mark and user manual). Cerebral oximetry will be recorded using a new small portable device (HR500, Nonin, USA). This device allows using an easy to use adhesive sensor with remote Bluetooth connection to a smartphone sized monitor.

  • Active Comparator: Assigned Intervention
    During the post-intervention period, patients assigned in the intervention group will receive the evaluated intervention (i.e., HUP and ACD-ITD CPR HUP using the 3 devices in combinations, Elegard, Lucas AD and ITD-16)
    Interventions:
    • Device: Head UP Position
    • Device: Impedance Threshold Device
    • Device: New Automated CPR
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: June 20, 2019)
194
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE January 2022
Estimated Primary Completion Date October 9, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Age > 18 years old on enrollment
  • Witnessed out-of-hospital cardiac arrest

Exclusion Criteria:

  • Obvious pregnancy at inclusion
  • Cardiac arrest of traumatic origin (including drowning or hanging)
  • Cardiac arrest for which resuscitation seems unjustified (inevitable death, terminally ill irreversible condition, too long duration of cardiac arrest, advance personal directives of no-resuscitation)
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Guillaume DEBATY, MD 0033476634202 gdebaty@chu-grenoble.fr
Contact: Caroline Sanchez, PhD 0033476634256 csanchez5@chu-grenoble.fr
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03996616
Other Study ID Numbers  ICMJE GRAVITY
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Study protocol will be submitted for publication. IPD will be shared with other researcher
Supporting Materials: Study Protocol
Supporting Materials: Statistical Analysis Plan (SAP)
Supporting Materials: Informed Consent Form (ICF)
Supporting Materials: Clinical Study Report (CSR)
Time Frame: Data will be available within 6 months of study completion
Access Criteria: Data will be available with no restriction
Responsible Party University Hospital, Grenoble
Study Sponsor  ICMJE University Hospital, Grenoble
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Monique Sorentino CHU Grenoble Alpes
PRS Account University Hospital, Grenoble
Verification Date November 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP